Company Overview of F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd. provides in-vitro diagnostics and drugs for cancer and transplantation. The company specializes in medicines for oncology, virology, inflammation, metabolism, CNS, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. Its products include cancer treatments, such as Avastin, Herceptin, and MabThera that are also effective in the treatment of rheumatoid arthritis, anemia, and osteoporosis. The company also researches, develops, and produces molecular diagnostic reagents, test systems, and test kits. In addition, it provides automated instruments, software, consumables, and IT solutions used in in-vitro diagnostic...
Founded in 1896
Key Executives for F. Hoffmann-La Roche Ltd
Chief Executive Officer of Roche Group
Compensation as of Fiscal Year 2014.
F. Hoffmann-La Roche Ltd Key Developments
F. Hoffmann-La Roche Ltd Announces Results from Phase III HER2-Positive Breast Cancer Study
Jan 6 15
F. Hoffmann-La Roche Ltd. has announced results from a Phase III MARIANNE study, which evaluates three HER2-targeted regimens, Kadcyla plus Perjeta, Kadcyla alone, and Herceptin plus taxane chemotherapy, in people with previously untreated advanced HER2-positive breast cancer. The study showed the three regimens helped people live without their disease worsening (PFS) for a similar amount of time, meeting its non-inferiority endpoint as assessed by an Independent Review Committee (IRC). However, neither Kadcyla-containing treatment arm significantly improved PFS compared to Herceptin and chemotherapy. Adverse events observed in the two experimental arms of the study were generally consistent with those seen in previous studies of Kadcyla and/or Perjeta. In their approved uses for advanced HER2-positive breast cancer, Kadcyla and Perjeta have been shown to extend survival. Kadcyla is approved for people with previously treated disease (second and later lines). Perjeta is approved in combination with Herceptin and chemotherapy for people with previously untreated disease (first line). The Phase III MARIANNE study (NCT01120184; BO22589) is an international, randomized, multicenter, three-arm study involving 1,095 people with HER2-positive advanced breast cancer - either with inoperable locally advanced disease that had worsened during or returned after previous treatment, or with disease that had spread to other areas of the body. People with advanced breast cancer at diagnosis and people whose disease had worsened following either neoadjuvant or adjuvant treatment were eligible. People enrolled in the study received treatment with either: A combination of Kadcyla and Perjeta; Kadcyla alone, or Herceptin and either docetaxel or paclitaxel chemotherapy. The primary endpoint of the MARIANNE study is PFS as assessed by an Independent Review Committee (IRC). Secondary endpoints include overall survival, response rate, and the incidence of adverse events. Differences in these endpoints were assessed in each of the Kadcyla-containing treatment arms compared to the Herceptin plus chemotherapy arm, and also between the two Kadcyla-containing arms.
F. Hoffmann-La Roche Ltd Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015
Dec 24 14
F. Hoffmann-La Roche Ltd Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
F. Hoffmann-La Roche Ltd Presents at DbAccess Pharmaceutical Corporate Day, Dec-04-2014
Dec 1 14
F. Hoffmann-La Roche Ltd Presents at DbAccess Pharmaceutical Corporate Day, Dec-04-2014 . Venue: Winchester House, London, United Kingdom.
Similar Private Companies By Industry
Recent Private Companies Transactions